Hudson Bay Capital Management
MRSN

Hudson Bay Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Hudson Bay Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-38,494
Closed -$3.17M – 899
2023
Q2 		$3.17M Buy
38,494
+25,494
+196% +$3.73M 0.02% 409
2023
Q1 		$1.34M Buy
13,000
+2,000
+18% +$281K 0.01% 567
2022
Q4 		$1.61M Buy
11,000
+1,200
+12% +$203K 0.02% 633
2022
Q3 		$1.66M Sell
9,800
-6,200
-39% -$1.01M 0.01% 772
2022
Q2 		$1.85M Sell
16,000
-1,400
-8% -$132K 0.01% 824
2022
Q1 		$1.74M Buy
17,400
+5,800
+50% +$678K 0.02% 735
2021
Q4 		$1.8M Buy
11,600
+4,600
+66% +$895K 0.02% 710
2021
Q3 		$1.65M Buy
7,000
+4,200
+150% +$1.23M 0.02% 675
2021
Q2 		$951K Buy
+2,800
New +$1.06M 0.01% 746

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Hudson Bay Capital Management's MRSN Position: Q3 2023 in Review

Hudson Bay Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 38,494 shares — an estimated $3.17M sold.

Hudson Bay Capital Management first reported a position in MRSN in Q2 2021 and held it in 9 quarters. The position peaked at $3.17M in Q2 2023. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Hudson Bay Capital Management reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 38,494 Mersana Therapeutics shares in Q3 2023, an estimated $3.17M.
  • Hudson Bay Capital Management first reported a position in Mersana Therapeutics in Q2 2021 and held it in 9 quarters.
  • Hudson Bay Capital Management's Mersana Therapeutics position peaked at $3.17M in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Hudson Bay Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.